Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacologic therapy for stop mutations: how much CFTR activity is enough?

Eitan Kerem1

  • 1Department of Pediatrics and Cystic Fibrosis Center, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel. ek@cc.huji.ac.il

Current Opinion in Pulmonary Medicine
|October 29, 2004
PubMed
Summary

Aminoglycoside antibiotics can help correct genetic defects in cystic fibrosis transmembrane conductance regulator (CFTR) by suppressing premature stop mutations. Clinical studies show gentamicin can restore CFTR function in patients, with some experiencing normalized transport.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-infectious bronchiolitis obliterans in children: pathogenesis, treatment strategies, and future directions.

Current opinion in pediatrics·2026
Same author

Clinical characteristics and outcomes in the adult cystic fibrosis population in Europe from 2014 to 2024: analysis of the European Cystic Fibrosis Society Patient Registry.

The Lancet. Respiratory medicine·2026
Same author

Henry Levison, a Giant of Pediatric Respiratory Medicine.

Pediatric pulmonology·2026
Same author

Author Correction: Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial.

Nature communications·2026
Same author

Intestinal organoids as a platform for functional evaluation of ASO-mediated splicing modulation in cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

The response of rare CFTR mutations to specific modulator combinations.

ERJ open research·2025

Area of Science:

  • Genetics
  • Molecular Biology
  • Pharmacology

Background:

  • Cystic fibrosis (CF) is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
  • Class I mutations, specifically premature stop mutations, represent 5-10% of CFTR defects.
  • These mutations lead to truncated, non-functional CFTR protein.

Purpose of the Study:

  • To review recent therapeutic strategies targeting the molecular mechanisms of CFTR mutations.
  • To focus on mutation-specific therapies for premature stop mutations (Class I).
  • To evaluate the efficacy of aminoglycoside antibiotics in correcting CFTR defects.

Main Methods:

  • Review of in vitro studies, animal models (mice), and clinical trials involving aminoglycosides.

Related Experiment Videos

  • Analysis of studies using gentamicin for topical nasal application in CF patients with stop mutations.
  • Examination of electrophysiological and immunohistochemical data from clinical studies.

    • Main Results:

    • Aminoglycosides suppress premature stop codons, allowing for increased CFTR expression and functional protein restoration.
    • In vitro and mouse studies demonstrated dose-dependent increases in CFTR expression and membrane localization.
    • Clinical trials showed topical gentamicin restored CFTR function in nasal epithelia of CF patients, with significant improvements in ion transport in a majority of participants.

    Conclusions:

    • Aminoglycosides, like gentamicin, show promise in treating CF caused by premature stop mutations.
    • Further research is needed to determine the optimal level of CFTR correction for clinical benefit.
    • Development of safer, more effective stop-codon suppressors for early diagnosis and treatment in children is a key future goal.